Fulton Breakefield Broenniman LLC trimmed its holdings in shares of Clorox Co (NYSE:CLX) by 1.6% in the fourth quarter, HoldingsChannel reports. The firm owned 84,050 shares of the company’s stock after selling 1,353 shares during the period. Clorox makes up about 2.3% of Fulton Breakefield Broenniman LLC’s portfolio, making the stock its 9th biggest holding. Fulton Breakefield Broenniman LLC’s holdings in Clorox were worth $12,956,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of the company. Meeder Asset Management Inc. purchased a new stake in Clorox in the 4th quarter worth approximately $26,000. City Holding Co. grew its stake in Clorox by 150.0% in the 4th quarter. City Holding Co. now owns 250 shares of the company’s stock worth $39,000 after acquiring an additional 150 shares during the period. G&S Capital LLC grew its stake in Clorox by 46.4% in the 4th quarter. G&S Capital LLC now owns 262 shares of the company’s stock worth $40,000 after acquiring an additional 83 shares during the period. Sonora Investment Management LLC purchased a new stake in Clorox in the 4th quarter worth approximately $50,000. Finally, Ipswich Investment Management Co. Inc. purchased a new stake in Clorox in the 4th quarter worth approximately $73,000. 82.60% of the stock is owned by institutional investors and hedge funds.
Shares of NYSE CLX opened at $155.70 on Monday. Clorox Co has a 52-week low of $113.57 and a 52-week high of $167.70. The firm has a market cap of $19.95 billion, a PE ratio of 24.87, a P/E/G ratio of 3.86 and a beta of 0.29. The company has a debt-to-equity ratio of 3.08, a current ratio of 1.15 and a quick ratio of 0.66.
Clorox (NYSE:CLX) last posted its earnings results on Monday, February 4th. The company reported $1.40 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.08. The business had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.47 billion. Clorox had a net margin of 12.65% and a return on equity of 105.97%. The business’s quarterly revenue was up 4.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.77 EPS. As a group, sell-side analysts expect that Clorox Co will post 6.33 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, February 8th. Investors of record on Wednesday, January 23rd were issued a dividend of $0.96 per share. The ex-dividend date of this dividend was Tuesday, January 22nd. This represents a $3.84 annualized dividend and a dividend yield of 2.47%. Clorox’s payout ratio is 61.34%.
Several research firms have commented on CLX. Zacks Investment Research raised shares of Clorox from a “sell” rating to a “hold” rating in a research note on Monday, January 7th. Wells Fargo & Co reaffirmed a “hold” rating and issued a $157.00 target price on shares of Clorox in a research note on Monday, February 4th. Bank of America reaffirmed a “neutral” rating and issued a $170.00 target price (up from $150.00) on shares of Clorox in a research note on Thursday, December 6th. Morgan Stanley set a $142.00 price objective on shares of Clorox and gave the company a “sell” rating in a research note on Thursday, December 20th. Finally, Barclays set a $138.00 price objective on shares of Clorox and gave the company a “hold” rating in a research note on Thursday, November 1st. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $149.08.
In related news, CAO Jeff Baker sold 3,694 shares of Clorox stock in a transaction on Friday, December 7th. The shares were sold at an average price of $162.56, for a total transaction of $600,496.64. Following the transaction, the chief accounting officer now owns 5,743 shares in the company, valued at approximately $933,582.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Benno O. Dorer sold 152,449 shares of Clorox stock in a transaction on Tuesday, December 4th. The shares were sold at an average price of $164.83, for a total transaction of $25,128,168.67. Following the transaction, the chief executive officer now owns 111,735 shares in the company, valued at approximately $18,417,280.05. The disclosure for this sale can be found here. Insiders have sold a total of 256,728 shares of company stock worth $41,973,324 in the last 90 days. Company insiders own 1.40% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.thelincolnianonline.com/2019/02/11/fulton-breakefield-broenniman-llc-sells-1353-shares-of-clorox-co-clx.html.
Clorox Company Profile
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.
Featured Story: Federal Reserve
Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Co (NYSE:CLX).
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.